Price Action to Note: Cardiovascular Systems Inc Rises A lot Today, Is Now One of The Best Performer

Price Action to Note: Cardiovascular Systems Inc Rises A lot Today, Is Now One of The Best Performer

The stock of Cardiovascular Systems Inc (NASDAQ:CSII) is a huge mover today! About 236,363 shares traded hands. Cardiovascular Systems Inc (NASDAQ:CSII) has risen 133.40% since March 7, 2016 and is uptrending. It has outperformed by 125.80% the S&P500.
The move comes after 9 months positive chart setup for the $844.08 million company. It was reported on Oct, 10 by Barchart.com. We have $36.26 PT which if reached, will make NASDAQ:CSII worth $371.40 million more.

Analysts await Cardiovascular Systems Inc (NASDAQ:CSII) to report earnings on November, 2. They expect $-0.19 EPS, up 53.66% or $0.22 from last year’s $-0.41 per share. After $-0.15 actual EPS reported by Cardiovascular Systems Inc for the previous quarter, Wall Street now forecasts 26.67% negative EPS growth.

Cardiovascular Systems Inc (NASDAQ:CSII) Ratings Coverage

Out of 6 analysts covering Cardiovascular Systems (NASDAQ:CSII), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. Cardiovascular Systems has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Zacks upgraded Cardiovascular Systems Inc (NASDAQ:CSII) on Friday, August 21 to “Sell” rating. The rating was downgraded by Zacks on Thursday, September 3 to “Sell”. The stock has “Underperform” rating given by Bank of America on Thursday, October 8. The rating was downgraded by Needham to “Underperform” on Friday, January 22. The company was maintained on Wednesday, June 29 by Needham. The firm has “Neutral” rating by Bank of America given on Thursday, August 4. Leerink Swann upgraded Cardiovascular Systems Inc (NASDAQ:CSII) on Monday, August 22 to “Outperform” rating. The firm has “Buy” rating by Needham given on Friday, April 1. The stock of Cardiovascular Systems Inc (NASDAQ:CSII) has “Buy” rating given on Thursday, October 8 by Dougherty & Company. Needham downgraded the shares of CSII in a report on Thursday, October 8 to “Buy” rating.

According to Zacks Investment Research, “Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360° Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360° removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its orbital technology to address the growing market need of providing a safer more effective atherectomy device.”

Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.42, from 0.9 in 2016Q1. The ratio is positive, as 7 funds sold all Cardiovascular Systems Inc shares owned while 30 reduced positions. 15 funds bought stakes while 34 increased positions. They now own 22.60 million shares or 20.49% more from 18.76 million shares in 2016Q1.
Menta Cap Ltd Liability accumulated 0.05% or 20,021 shares. First Republic, a California-based fund reported 13,727 shares. Moreover, Blackrock Advisors Ltd has 0% invested in Cardiovascular Systems Inc (NASDAQ:CSII) for 15,089 shares. Secor Cap Advsrs Limited Partnership last reported 27,006 shares in the company. Tiaa Cref Invest Ltd has 0% invested in the company for 134,298 shares. Moreover, Elkhorn Prns Ltd Partnership has 0.16% invested in Cardiovascular Systems Inc (NASDAQ:CSII) for 13,000 shares. Geneva Advsrs Ltd Liability Com holds 0.01% of its portfolio in Cardiovascular Systems Inc (NASDAQ:CSII) for 15,330 shares. Legal And General Group Public Limited owns 4,815 shares or 0% of their US portfolio. Moreover, Apriem Advsr has 0% invested in Cardiovascular Systems Inc (NASDAQ:CSII) for 200 shares. The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Cardiovascular Systems Inc (NASDAQ:CSII). Voya Investment Management Ltd has 15,613 shares for 0% of their US portfolio. Meeder Asset Mngmt holds 0.05% of its portfolio in Cardiovascular Systems Inc (NASDAQ:CSII) for 29,477 shares. Us Savings Bank De accumulated 7,617 shares or 0% of the stock. Moreover, Wellington Mngmt Grp Llp has 0.01% invested in Cardiovascular Systems Inc (NASDAQ:CSII) for 2.72 million shares. Moreover, Blackrock Gru has 0% invested in Cardiovascular Systems Inc (NASDAQ:CSII) for 11,695 shares.

More recent Cardiovascular Systems Inc (NASDAQ:CSII) news were published by: Fool.com which released: “Why Cardiovascular Systems Inc’s Stock Flatlined Today” on January 23, 2016. Also Bizjournals.com published the news titled: “Former Cardiovascular Systems CEO David Martin dies at 51” on May 05, 2016. Prnewswire.com‘s news article titled: “Shareholder Class Action Filed Against Cardiovascular Systems, Inc. – CSII” with publication date: February 18, 2016 was also an interesting one.

CSII Company Profile

Cardiovascular Systems, Inc., incorporated on December 6, 2000, is a medical technology company. The Firm is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Firm develops an orbital atherectomy technology for both peripheral and coronary commercial applications. The Company’s peripheral artery disease (PAD) systems are catheter platforms capable of treating a range of plaque types in leg arteries both above and below the knee. The Company’s products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment